机译:Nivolumab或Nivolumab在复发恶性胸膜间皮瘤患者中加入IPILIMIMAB(IFCT-1501 MAPS2):多期,开放标签,随机,非比较,阶段2试验
Univ Lille Univ Hosp CHU Lille Dept Pulm &
Thorac Oncol F-59037 Lille France;
Univ Paul Sabatier Univ Hosp Toulouse Dept Pneumol Toulouse France;
Aix Marseille Univ AP HP Multidisciplinary Oncol &
Therapeut Innovat Dept Marseille France;
Ctr Lutte Canc Leon Berard Dept BioPathol MESOPATH Lyon France;
Ctr Lutte Canc Baclesse Dept Pneumol Caen France;
Hop Instruct Armees Dept Pneumol Clamart France;
Ctr Hosp Intercommunal Creteil Dept Pneumol Creteil France;
Univ Hosp Rennes Dept Pneumol Rennes France;
Hop St Musse Dept Pneumol Toulon France;
Ctr Hosp Lyon Sud Pierre Benite Dept Pneumol Lyon France;
Le Mans Reg Hosp Dept Pneumol Le Mans France;
Univ Hosp Rouen Dept Pneumol Rouen France;
CHU Angers Univ Hosp Dept Pneumol Angers France;
Clin Mutualiste Estuaire Dept Med Oncol St Nazaire France;
Inst Gustave Roussy Dept Thorac Oncol Villejuif France;
IFCT Paris France;
IFCT Paris France;
Univ Hosp Grenoble Dept Pneumol Grenoble France;
Paris Diderot Univ Paris Univ Hosp Bichat Claude Bernard AP HP Paris France;
机译:Nivolumab或Nivolumab加上恶性胸膜间皮瘤患者的IPILIMIMAB(IFCT-1501 MAPS2):多期,开放标签,随机,非比较,第2期试验(VOL 20,PG 239,2019)
机译:Nivolumab或Nivolumab在复发恶性胸膜间皮瘤患者中加入IPILIMIMAB(IFCT-1501 MAPS2):多期,开放标签,随机,非比较,阶段2试验
机译:Nivolumab或Nivolumab在复发恶性胸膜间皮瘤患者中加入IPILIMIMAB(IFCT-1501 MAPS2):多期,开放标签,随机,非比较,阶段2试验
机译:可行性试验评估腹膜内光动力学治疗与胸膜切除术/凝固患者患者在恶性胸膜间皮瘤患者中相结合。
机译:恶性胸膜间皮瘤患者在标准化疗中加用贝伐单抗的经济分析。
机译:NIPU:随机开放标签II期研究评估Nivolumab和Ipilimumab与UV1疫苗接种作为恶性间皮瘤患者的第二线治疗
机译:在不可切除的恶性胸膜间皮瘤(Checkmate 743)中,第一线Nivolumab加Ipilemimab:多期,随机,开放标签,第3阶段试验